Ipsen SA IPSEF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IPSEF is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $117.60
- Day Range
- $132.50–132.50
- 52-Week Range
- $108.75–132.50
- Bid/Ask
- $105.22 / $119.91
- Market Cap
- $10.98 Bil
- Volume/Avg
- 3,623 / 2,169
Key Statistics
- Price/Earnings (Normalized)
- 13.54
- Price/Sales
- 3.09
- Dividend Yield (Trailing)
- 0.98%
- Dividend Yield (Forward)
- 0.98%
- Total Yield
- 0.98%
Company Profile
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Core
- Total Number of Employees
- 5,325
- Website
- https://www.ipsen.com
Competitors
Valuation
|
Metric
|
IPSEF
|
UCB
|
EXEL
|
|---|---|---|---|
Price/Earnings (Normalized) | 13.54 | 37.37 | 23.50 |
Price/Book Value | 2.59 | 3.22 | 3.24 |
Price/Sales | 3.09 | 5.45 | 4.01 |
Price/Cash Flow | 13.31 | 41.71 | 21.60 |
Price/Earnings
IPSEF
UCB
EXEL
Financial Strength
|
Metric
|
IPSEF
|
UCB
|
EXEL
|
|---|---|---|---|
Quick Ratio | 0.86 | 0.75 | 3.23 |
Current Ratio | 1.17 | 1.19 | 3.46 |
Interest Coverage | 21.20 | 3.15 | — |
Quick Ratio
IPSEF
UCB
EXEL
Profitability
|
Metric
|
IPSEF
|
UCB
|
EXEL
|
|---|---|---|---|
Return on Assets (Normalized) | 12.69% | 4.48% | 9.61% |
Return on Equity (Normalized) | 21.64% | 7.73% | 12.20% |
Return on Invested Capital (Normalized) | 19.82% | 6.73% | 8.59% |
Return on Assets
IPSEF
UCB
EXEL
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Gmbpkmbgsf | Lpf | $82.1 Bil | |||
| Merck KGaA ADR
MKKGY
| Xkqpnfgsl | Ctvntkd | $75.2 Bil | |||
| Haleon PLC ADR
HLN
| Bcqjvnq | Rrhb | $41.4 Bil | |||
| Viatris Inc
VTRS
| Rbwmfbkdc | Lxx | $14.4 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Bbjzlnxm | Cfrmm | $13.7 Bil | |||
| Catalent Inc
CTLT
| Hlwmgcwt | Pffyj | $10.6 Bil | |||
| Perrigo Co PLC
PRGO
| Nkbdbfy | Fypy | $3.8 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Mbslzpgw | Pktncn | $3.5 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Lqxxwzpqd | Bbpml | $3.0 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Fqphftxpn | Kjch | $2.7 Bil |